Obesity promotes a chronic inflammatory and hypercoagulable state that drives cardiovascular disease, type 2 diabetes, fatty liver disease, and several cancers. Elevated thrombin activity underlies obesity-linked thromboembolic events, but the mechanistic links between the thrombin/fibrin(ogen) axis and obesity-associated pathologies are incompletely understood. In this work, immunohistochemical studies identified extravascular fibrin deposits within white adipose tissue and liver as distinct features of mice fed a high-fat diet (HFD) as well as obese patients. Fibγ390–396A mice carrying a mutant form of fibrinogen incapable of binding leukocyte αMβ2-integrin were protected from HFD-induced weight gain and elevated adiposity. Fibγ390–396A mice had markedly diminished systemic, adipose, and hepatic inflammation with reduced macrophage counts within white adipose tissue, as well as near-complete protection from development of fatty liver disease and glucose dysmetabolism. Homozygous thrombomodulin-mutant ThbdPro mice, which have elevated thrombin procoagulant function, gained more weight and developed exacerbated fatty liver disease when fed a HFD compared with WT mice. In contrast, treatment with dabigatran, a direct thrombin inhibitor, limited HFD-induced obesity development and suppressed progression of sequelae in mice with established obesity. Collectively, these data provide proof of concept that targeting thrombin or fibrin(ogen) may limit pathologies in obese patients.

Find the latest version:

https://jci.me/92744/pdf
Thrombin promotes diet-induced obesity through fibrin-driven inflammation

Anna K. Kopek,1 Sara R. Abrahams,2 Sherry Thornton,3 Joseph S. Palumbo,4 Eric S. Mullins,4 Senad Divanovic,5 Hartmut Weiler,6 A. Phillip Owens III,7 Nigel Mackman,8 Ashley Goss,9 Joanne van Ryn,10 James P. Luyendyk,1 and Matthew J. Flick2

1Department of Pathobiology and Diagnostic Investigation, Institute for Integrative Toxicology, Michigan State University, East Lansing, Michigan, USA. 2Division of Experimental Hematology and Cancer Biology, 3Department of Rheumatology, 4Division of Hematology, and 5Division of Immunobiology, Cincinnati Children’s Hospital Research Foundation, Cincinnati, Ohio, USA. 6Department of Physiology, Blood Center of Wisconsin, Milwaukee, Wisconsin, USA. 7Division of Cardiovascular Health and Disease, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA. 8Thrombosis and Hemostasis Program, Division of Hematology and Oncology, Department of Medicine, UNC McAlester Heart Institute, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 9Department of Cardiometabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, USA. 10Department of Cardiometabolic Disease Research, Boehringer Ingelheim Pharma GmbH, Biberach, Germany.

Obesity promotes a chronic inflammatory and hypercoagulable state that drives cardiovascular disease, type 2 diabetes, fatty liver disease, and several cancers. Elevated thrombin activity underlies obesity-linked thromboembolic events, but the mechanistic links between the thrombin/fibrinogen axis and obesity-associated pathologies are incompletely understood. In this work, immunohistochemical studies identified extravascular fibrin deposits within white adipose tissue and liver as distinct features of mice fed a high-fat diet (HFD) as well as obese patients. Fibγ390–396A mice carrying a mutant form of fibrinogen incapable of binding leukocyte αvβ3-integrin were protected from HFD-induced weight gain and elevated adiposity. Fibγ390–396A mice had markedly diminished systemic, adipose, and hepatic inflammation with reduced macrophage counts within white adipose tissue, as well as near-complete protection from development of fatty liver disease and glucose dysmetabolism. Homozygous thrombomodulin-mutant ThbdG20210A mice, which have elevated thrombin procoagulant function, gained more weight and developed exacerbated fatty liver disease when fed a HFD compared with WT mice. In contrast, treatment with dabigatran, a direct thrombin inhibitor, limited HFD-induced obesity development and suppressed progression of sequelae in mice with established obesity. Collectively, these data provide proof of concept that targeting thrombin or fibrinogen may limit pathologies in obese patients.

Introduction

Obesity is a health care crisis of global pandemic status, with an estimated 34% of adults and 17% of children in the United States classified as obese as defined by a BMI greater than or equal to 30 kg/m² (1). The detrimental effects of obesity are due to the fact that it induces a state of chronic "metabolic inflammation" whereby the control of energy and metabolites in adipose, liver, and muscle tissue is directed largely by innate immune cells (e.g., macrophages) and soluble effector molecules (e.g., cytokines) (2–7). Metabolic inflammation predisposes individuals to metabolic syndrome and associated comorbidities, including cardiovascular disease, type 2 diabetes (T2D), nonalcoholic fatty liver disease (NAFLD), osteoarthritis, and various cancers that are the most frequent causes of death in the United States and most Westernized countries (1, 8).

Obesity is also characterized as a hypercoagulable state. Association studies have documented elevated circulating levels of von Willebrand factor, fibrinogen, factor VII, and biomarkers of coagulation activity (e.g., thrombin-antithrombin [TAT] complexes, thrombin f1+2, D-dimer) in obese individuals (9–11). Activated protein C (APC) resistance increases with BMI, in part because of elevated factor VIII levels (12). A Mendelian randomization study determined that the risk of deep vein thrombosis increased 3.4-fold for severely obese patients compared with normal-weight individuals (13). More notably, both initial risk and severe morbidity and mortality outcomes for vaso-occlusive diseases (e.g., coronary artery disease and stroke) positively correlate with the degree of obesity in patients (9, 10, 14, 15). Collectively, these observations support the notion that obesity increases the risk of thromboembolic disease.

Emergent observations in obese patients have suggested a reciprocal relationship between the thrombin/fibrinogen axis and obesity/metabolic inflammation. A genetic association analysis to evaluate the correlation of thrombophilia mutations with superficial vein thrombosis determined that factor VLeiden is independently associated with a BMI greater than or equal to 28 kg/m² (16). Levels of procoagulant factors (e.g., fibrinogen, factor VII, factor VIII) are higher in obese patients with T2D than in those without T2D (17). Multiple thrombotic risk factors (e.g., APC resistance, protein S/protein C deficiency, prothrombin G20210A) are not only frequently present in patients with
NAFLD, but are associated with the severe form of this disease, nonalcoholic steatohepatitis (NASH), and advanced liver fibrosis (18). Although these association studies are highly intriguing and have serious potential clinical implications, significant knowledge gaps remain, including whether elevated thrombin activity and adipose fibrin deposits are causative factors in obesity and the identification of potential mechanisms linking thrombin and fibrin to obesity sequelae.

Here, we directly explored the hypothesis that fibrinogen and thrombin activity exacerbate diet-induced obesity, metabolic inflammation, and associated sequelae. To test this hypothesis, mice carrying genetically imposed deficiencies or functional mutations in fibrinogen, factor XIII, thrombomodulin, or protease-activated receptor-1 (PAR1) were analyzed for changes in body weight gain and altered inflammatory and metabolic parameters in both adipose tissue and liver. Our findings provide a mechanistic link between elevated procoagulant function and fibrinogen-driven inflammation in adipose and liver to exacerbation of obesity and obesity-associated sequelae. Further, in proof-of-concept studies using the direct thrombin inhibitor dabigatran etexilate, we demonstrate that inhibiting thrombin activity ameliorates the development of obesity and severity of associated sequelae.

Results

Fibrinogen drives high-fat diet-induced obesity through the \( \gamma^{390-396} \alpha_{3}\beta_{3} \)-binding motif. To investigate whether fibrinogen could contribute to diet-induced obesity, fibrinogen immunohistochemistry was performed on epididymal white adipose tissue and liver sections from WT mice fed either a control diet (CD) or a high-fat diet (HFD) for 16 weeks. Little to no fibrinogen deposits were detected in either adipose (Figure 1A) or liver (Figure 1B) from mice fed a CD. However, robust fibrinogen deposits were found throughout the extravascular spaces between hypertrophic adipocytes in HFD-fed mice (Figure 1A). The most intense fibrinogen staining appeared to be in areas between adipocytes in regions with macrophage accumulation in what have been termed “crown” structures (19). Fibrinogen staining was present throughout the liver sinusoids of HFD-fed mice that showed evidence of steatosis (Figure 1B). Importantly, sections of visceral adipose tissue from obese patients revealed a similar pattern with extravascular fibrinogen deposits present in the adipose tissue and most intense in macrophage-rich “crown” structures (Figure 1A). Extravascular fibrinogen deposits were absent in visceral adipose from nonobese individuals. Similarly, liver sections from obese patients with NASH displayed robust fibrinogen deposits in the sinusoids, whereas liver sections with a normal histological presentation were fibrinogen-free (Figure 1B). Collectively, these findings support the concept that fibrinogen could contribute to obesity pathogenesis in both humans and mice.

To gain mechanistic insight into the role of fibrinogen in HFD-induced obesity, we used 2 complementary mouse strains expressing function-selective variants of fibrinogen: (a) Fbg \( 390-396A \) (hereafter termed \( \text{Fib}_390-396A \)) mice, which express a mutant form of fibrinogen that has normal clotting function but lacks the binding motif for the leukocyte integrin receptor \( \alpha_{3}\beta_{3} \), and (b) \( \text{Fib}_5 \) (hereafter termed \( \text{Fib}_5 \)) mice, expressing a homozygous deletion in fibrinogen for the final 5 amino acids of the \( \gamma \) chain that encode the platelet integrin \( \alpha_{2}\beta_{1} \)-binding motif. Cohorts of WT and \( \text{Fib}_390-396A \) mice were fed a CD and HFD (60% of kcal from fat) for 20 weeks. A marked and statistically significant protection from body weight gain was observed in \( \text{Fib}_390-396A \) mice fed the HFD compared with HFD-fed WT mice (Figure 2A), with no effect of genotype on body weight gain in mice fed CD. The difference in body weight between HFD-fed \( \text{Fib}_390-396A \) and WT mice was significant as early as 4 weeks after starting on the HFD, and the differential increased throughout the 20-week HFD period (Figure 2, B and C, respectively). Body mass composition analysis revealed that the difference in body weight was secondary to reduced fat mass in \( \text{Fib}_390-396A \) mice compared with WT mice, as analyzed at 12 and 16 weeks on HFD (Figure 2, D and E, respectively). Further, the epididymal and inguinal white adipose tissue (eWAT and iWAT, respectively) depots isolated from HFD-fed \( \text{Fib}_390-396A \) mice at the end of the challenge period were significantly smaller than eWAT and iWAT from HFD-fed WT mice (Figure 2, F and G).

In contrast, \( \text{Fib}_5 \) mice fed an identical 60% HFD gained the same amount of weight as WT mice over the course of the challenge period (Figure 2H). Total body weights of CD-fed or HFD-fed mice were not different between WT and \( \text{Fib}_5 \) mice at any time point during the challenge period (see Figure 2, I and J, for representative time points of 9 weeks and 16 weeks, respective-
To determine whether the protection from HFD-induced weight gain observed in Fibγ390–396A mice was limited to the specific diet tested, we evaluated weight gain in mice using a separate set of diets. Here, a HFD formulated to 45% of kcal from fat was used with a corresponding CD with 10% of kcal from fat. Similar to analyses using the 60% HFD, Fibγ390–396A mice fed the CD showed a significantly lower weight gain compared to WT mice (A–G). No genotype-dependent differences in the weight of eWAT (Figure 2K), iWAT (Figure 2L), or liver (not shown) were observed in tissues harvested at the end of the challenge period for either CD-fed or HFD-fed WT and FibγΔ5 mice. Collectively, these findings indicate that the γ390–396 motif of fibrin(ogen) specifically promotes HFD-induced obesity.

To address the hypothesis that the protective effect was specific to the HFD, we performed additional analyses using the 60% HFD. Similar to the 60% HFD, Fibγ390–396A mice showed a significantly lower weight gain compared to WT mice (H–L). No genotype-dependent differences in the weight of eWAT (Figure 3K), iWAT (Figure 3L), or liver (not shown) were observed in tissues harvested at the end of the challenge period for either CD-fed or HFD-fed WT and FibγΔ5 mice. Collectively, these findings indicate that the γ390–396 motif of fibrin(ogen) specifically promotes HFD-induced obesity.

Figure 3. Fibγ390–396A mice are protected from the development of HFD-driven obesity. (A–G) WT and Fibγ390–396A mice were fed either a CD (n = 4 mice per genotype) or a 60% HFD (n = 9 mice per genotype). (A) Mean body weights of WT and fibrinogen γ390–396A (Fibγ390-396A) mice over a 20-week feeding period. (B and C) Distribution of body weights for WT and Fibγ390-396A mice fed the CD or 60% HFD at week 4 (B) and week 20 (C) on diet. (D and E) Analysis of body mass composition of 60% HFD-fed WT and Fibγ390-396A mice performed at week 12 (D) and week 16 (E). (F and G) Total fat pad weights of eWAT (F) and iWAT (G) for WT and Fibγ390-396A mice at week 20. (H) Mean body weights of WT and fibrinogen γΔ5 (FibγΔ5) mice fed a CD (n = 3 mice per genotype) or 60% HFD (n = 14–15 mice per genotype) over a 16-week feeding period. (I and J) Analysis of individual body weights for WT and FibγΔ5 mice at week 9 (I) and week 16 (J) on diet. (K and L) Total fat pad weights of eWAT (K) and iWAT (L) for WT and FibγΔ5 mice at week 16. Data are expressed as the mean ± SEM. Data were analyzed by 2-way ANOVA with Student-Newman-Keuls post hoc test. *P < 0.05, **P < 0.01 for analyses comparing differences between genotypes on the same diet. *P < 0.05, **P < 0.01, ***P < 0.001 for analyses comparing differences between diets with mice of the same genotype.
The fibrinogen γ390–396 motif supports binding to the coagulation transglutaminase factor XIII in addition to binding the leukocyte integrin receptor αMβ2 (23). To determine whether the decrease in body weight following HFD feeding observed in Fibγ390–396A mice relative to WT mice involved factor XIII, mice deficient in the catalytic A subunit of factor XIII (F13a1–/–) and WT mice were fed the 60% HFD and CD for 20 weeks. In contrast to results with Fibγ390–396A mice, weight gain of F13a1–/– mice was virtually identical to that of WT mice (Supplemental Figure 2, A–C). Similarly, there were no genotype-dependent differences in the weight of eWAT or liver for either CD-fed or HFD-fed WT and F13a1–/– mice (Supplemental Figure 2, D and E, respectively).

Fibγ390–396A mice are protected from the development of HFD-induced systemic and local inflammation. To determine whether the lower body weight gain and fatty liver disease observed in HFD-fed Fibγ390–396A mice were indeed linked to a reduction in systemic and local inflammation, we first measured circulating proinflammatory cytokines/chemokines in plasma. TNF-α, MCP-1, and IL-17A have each been linked to exacerbation of obesity-associated sequelae (24–28), and each was significantly increased by HFD feeding in WT mice (Figure 2, A–C). Similarly, those mice had a significantly greater mass in eWAT compared with Fibγ390–396A mice (Supplemental Figure 1, D and E, respectively). The difference in weight gain displayed by the Fibγ390–396A mice on either the 60% or the 45% HFD could not be explained by differences in food consumption (Figure 3A and data not shown, respectively). In addition, the weight gain difference did not appear to be linked to differences in intestinal fat absorption, as no genotype-dependent difference in fat absorption was detected in mice fed a CD or HFD for 16 weeks (Figure 3B). However, HFD-fed WT mice overall displayed significantly higher fat absorption than CD-fed mice (Figure 3B), as previously described (22). Similarly, the difference in HFD-induced weight gain did not appear to be linked to differential compensatory changes in brown adipose tissue (BAT). As expected, the BAT weight in WT mice was significantly higher in HFD-fed animals than in CD-fed animals (Figure 3C). A significant increase was also observed for Fibγ390–396A mice when comparing CD- and HFD-fed animals.
The fibrinogen \( \gamma^{390–396} \) mutation protected mice from HFD-induced fatty liver disease. (D) Steatosis in HFD-fed WT mice was accompanied by elevated liver weights and decreased liver ALT levels compared with those of HFD-fed \( \gamma^{390–396} \) mice (Figure 6A). This tracked with reduced liver triglyceride levels in HFD-fed \( \gamma^{390–396} \) mice compared with those of HFD-fed WT mice (Figure 6D). Notably, the fatty liver disease in HFD-fed WT mice was associated with significantly higher serum alanine aminotransferase activity in HFD-fed WT mice (Figure 6E). This suggests that the fibrinogen \( \gamma^{390–396} \) mutation protected mice from the development of HFD-induced fatty liver disease and glucose dysmetabolism.

To determine whether reduced weight gain in HFD-fed \( \gamma^{390–396} \) mice was linked to protection from the development of obesity sequelae, we first evaluated fatty liver disease. Histological analysis of liver sections revealed significant steatosis in HFD-fed WT mice but not in HFD-fed \( \gamma^{390–396} \) mice (Figure 6A). This tracked with reduced liver triglyceride levels in HFD-fed \( \gamma^{390–396} \) mice compared with those of HFD-fed WT mice (Figure 6D). Notably, the fatty liver disease in HFD-fed WT mice was associated with significantly higher serum alanine aminotransferase activity in HFD-fed WT mice (Figure 6E). This suggests that the fibrinogen \( \gamma^{390–396} \) mutation protected mice from the development of HFD-induced fatty liver disease and glucose dysmetabolism.
were protected from hepatocellular injury as indicated by serum ALT activity equivalent to that of CD-fed mice (Figure 6E). Hepatic inflammatory markers were also examined. Levels of Adgre1 mRNA were elevated in HFD-fed mice compared with CD-fed animals, but no genotype-dependent difference was observed (Figure 6F). Significantly reduced hepatic mRNA levels of Ccd2 and Tnf were observed in HFD-fed Fibγ390-396A mice compared with WT mice (Figure 6, G and H, respectively). The potential molecular basis of significantly diminished steatosis in Fibγ390-396A mice was revealed through analysis of gene products associated with lipid accumulation/lipogenesis. Hepatic mRNA levels of the nuclear receptor PPARγ (Pparg), the fatty acid sensor CIDEA (Cidea), and the fatty acid transporter CD36 (Cd36) were each significantly lower in HFD-fed Fibγ390-396A mice compared with WT mice (Figure 6, I–K, respectively).

HFD-mediated changes in glucose metabolism were also determined. Analysis of fasting blood glucose levels showed that HFD-fed mice of both genotypes had significantly higher blood glucose levels compared with CD-fed mice (Figure 7A). Importantly, glucose clearance was impaired by HFD challenge, but clearance was significantly more efficient in HFD-fed Fibγ390-396A mice compared with HFD-fed WT mice as analyzed by 2-hour glucose tolerance tests (Figure 7B). Similarly, HFD-fed WT mice displayed a profound loss of insulin sensitivity as shown by insulin tolerance tests compared with CD-fed mice. Insulin sensitivity in HFD-challenged Fibγ390-396A mice was significantly improved compared with that in HFD-fed WT mice (Figure 7C). Accordingly, we observed significantly elevated fasting insulin levels in HFD-fed mice compared with CD mice, but insulin levels were significantly lower in HFD-fed Fibγ390-396A mice compared with HFD-fed WT mice (Figure 8A). Consistent with differential body weights, the adipokines leptin and resistin were significantly higher in HFD-fed WT mice compared with HFD-fed Fibγ390-396A mice at 20 weeks (Figure 8, B and C, respectively). Interestingly, leptin, resistin, and adiponectin were each significantly lower in Fibγ390-396A mice compared with WT mice fed a CD (Figure 8, B–D, respectively).

Mice with a genetically imposed procoagulant state exhibit exacerbated obesity following a HFD challenge. The effect of diet and fibrinogen genotype on coagulation parameters was assessed by measurement of TAT, D-dimer, and platelet factor 4 (PF4) in the plasma of CD-fed and HFD-fed WT and Fibγ390-396A mice. HFD challenge resulted in significantly higher TAT and D-dimer levels in WT mice compared with CD-fed mice (Table 1). Notably, plasma levels of both of these coagulation markers were also elevated in Fibγ390-396A mice fed a HFD compared with a CD (Table 1). Plasma levels of the platelet activation marker PF4 were similar across diet and genotype (Table 1), suggesting that differential platelet activation was not the basis of fibrinogen genotype–dependent differences in HFD-induced obesity.

To investigate whether enhanced procoagulant function itself could alter the development of diet-induced obesity and obesity-associated disease sequelae, we evaluated HFD-induced obesity in mice homozygous for a Glu404Pro mutation in the thrombomodulin receptor (ThbdPro). ThbdPro mice exhibit a hypercoagulable state due to significantly reduced thrombin binding and disrupted thrombomodulin-dependent protein C activation by the mutant receptor. Both ThbdPro and WT animals gained significantly more weight on the HFD than cohorts of mice fed a CD (Supplemental Figure 3A). However, ThbdPro mice fed a HFD gained significantly more weight than WT mice fed a HFD (Supplemental Figure 3A). The significant genotype-dependent difference in body weight was first apparent at approximately 11 weeks on the HFD (Supplemental Figure 3B) and persisted through 16 weeks (Supplemental Figure 3C). MRI-based body mass composition revealed a significant increase in fat mass, but not lean mass, in HFD-fed ThbdPro mice at 12 and 16 weeks (Supplemental Figure 3, D and E, respectively). The
Figure 6. Fibγ390–396A mice are protected from the development of HFD-driven fatty liver disease and hepatocellular injury. WT and Fibγ390–396A mice were fed either a CD (n = 4 per genotype) or a 60% HFD (n = 12 per genotype) for 20 weeks. (A) Representative H&E-stained and fibrinogen (red) immunohistochemistry–stained sections of liver tissue. Note that liver tissue from HFD-fed WT mice revealed evidence of hepatic steatosis and sinusoidal fibrinogen deposits. Scale bars: 100 μm. (B) Total liver weights of mice following the 20-week diet challenge. (C) Quantification of fibrin deposits in CD-fed (n = 4 per genotype) and HFD-fed (n = 8 per genotype) WT and Fibγ390–396A mice. Data are presented as the mean ± SEM of the percent area of staining per high-powered field. (D) Analysis of liver triglyceride content confirmed significantly diminished hepatic steatosis in HFD-fed Fibγ390–396A mice relative to WT animals. (E) Analysis of circulating alanine aminotransferase (ALT) in CD- and HFD-fed WT and Fibγ390–396A mice indicated significantly reduced hepatocellular damage in HFD-fed Fibγ390–396A mice. (F–K) Hepatic levels of mRNA in liver tissue encoding the genes Adgre1 (F), Ccl2 (G), Tnf (H), Pparg (I), Cidea (J), and Cd36 (K) were determined by quantitative RT-PCR. Data are expressed as the mean ± SEM. Data were analyzed by 2-way ANOVA with Student-Newman-Keuls post hoc test. *P < 0.05, **P < 0.01, ***P < 0.001 for analyses comparing differences between genotypes on the same diet. *P < 0.05, **P < 0.01 for analyses comparing differences between diets with mice of the same genotype.
HFD-fed ThbdPro mice had significantly higher liver triglyceride levels than WT mice fed a HFD (Supplemental Figure 4C). Similarly, HFD-fed Thbd Pro mice had significantly higher ALT levels relative to HFD-fed WT mice and mice fed a CD (Supplemental Figure 4D). Inflammatory genes in the liver were not significantly elevated in HFD-fed ThbdPro mice compared with HFD-fed WT mice (Supplemental Figure 4, E–G). However, hepatic mRNA levels of the lipogenic genes Pparg, Cidea, and Cd36 (Supplemental Figure 4, H–J) were significantly higher in HFD-fed ThbdPro mice compared with HFD-fed WT mice. Taken together, these data indicate that defective thrombomodulin function exacerbates obesity-induced fatty liver disease.

HFD studies in Thbd Pro and Fibγ390–396A mice suggested that (a) dysregulated thrombin activity promotes obesity and (b) the mechanism of thrombin-driven obesity is linked to fibrinogen. To determine whether the mechanisms of thrombin-driven HFD-induced obesity could also be mediated through the thrombin substrate protease-activated receptor-1 (PAR1), we analyzed HFD-induced obesity using PAR1-deficient mice (F2r–/–). Cohorts of F2r–/– mice and WT mice were fed the same diet. (Supplemental Figure 4B). HFD-fed ThbdPro mice had significantly higher liver triglyceride levels than WT mice fed a HFD (Supplemental Figure 4C). Similarly, HFD-fed Thbd Pro mice had significantly higher ALT levels relative to HFD-fed WT mice and mice fed a CD (Supplemental Figure 4D). Inflammatory genes in the liver were not significantly elevated in HFD-fed ThbdPro mice compared with HFD-fed WT mice (Supplemental Figure 4, E–G). However, hepatic mRNA levels of the lipogenic genes Pparg, Cidea, and Cd36 (Supplemental Figure 4, H–J) were significantly higher in HFD-fed ThbdPro mice compared with HFD-fed WT mice. Taken together, these data indicate that defective thrombomodulin function exacerbates obesity-induced fatty liver disease.
more weight and fat mass compared with mice fed CD (Figure 9F). Importantly, the extent of weight gain in weeks 12–20 was markedly reduced in HFD-fed mice receiving DE compared with mice receiving HFD without DE, a change attributable to reduced accumulation of fat mass, not lean mass (Table 3). Differences in body weight could not be accounted for by differences in food consumption (not shown). Serum ALT activity increased dramatically in mice fed HFD from weeks 12 to 20, denoting the onset of hepatocellular injury and more severe NAFLD (Table 3). Serum ALT failed to increase in HFD-fed DE-treated mice (Table 3), indicating that in addition to limiting HFD-induced adiposity, DE treatment in established obesity suppresses the progression of existing NAFLD. Histological assessment of liver tissue from mice at the end of the 20-week evaluation period indicated lower extent of microvesicular steatosis, the form of lipid accumulation specified.

HFD and CD used in Fibγ390–396A and Thbd<sup>+/+<sup> studies (i.e., 60% of kcal from fat). Consistent with previous studies (32), no genotype-dependent difference in weight gain was observed in WT and F2r<sup>−/−</sup> mice on either diet (Supplemental Figure 5A). Indeed, the weights of individual HFD-fed WT and F2r<sup>−/−</sup> mice were comparable at multiple weeks on the diet (Supplemental Figure 5, B and C). Further, the weights of eWAT and livers isolated from WT and F2r<sup>−/−</sup> mice at the end of the challenge period were not different between CD-fed or HFD-fed animals (Supplemental Figure 5, D and E, respectively).

The direct thrombin inhibitor dabigatran etexilate protects mice from HFD-induced obesity development and successfully treats established obesity sequelae. In agreement with an earlier report (33), we found that prophylactic administration of dabigatran etexilate (DE) (7.5 mg/g diet) over the course of 20 weeks attenuated body weight gain (and fat mass) in mice fed a HFD (60% of kcal from fat) (Figure 9, A–C), indicating protection from obesity in 2 distinct HFD-induced obesity models. Our working hypothesis was that the beneficial effect of DE was through prevention of thrombin-mediated fibrin deposition in WAT of HFD-fed mice. DE treatment significantly reduced levels of high–molecular weight fibrin species (defined as >350 kDa) in extracts of eWAT from HFD-fed mice, as determined by capillary-based Western blotting (Figure 9D). The absence of these fibrin species in plasma clots formed using F13a1<sup>−/−<sup> plasma confirmed the identity of these species as prototypical cross-linked fibrin.

To address whether DE could rescue established obesity, mice were fed CD or HFD without the drug for 12 weeks to induce obesity (Table 2). The mice then continued to receive the same diet for an additional 8 weeks, but were randomized to receive diet with or without DE during this rescue arm of the study (Figure 9E). As expected, HFD-fed mice without DE continued to gain more weight and fat mass compared with mice fed CD (Figure 9F). Importantly, the extent of weight gain in weeks 12–20 was markedly reduced in HFD-fed mice receiving DE compared with mice receiving HFD without DE, a change attributable to reduced accumulation of fat mass, not lean mass (Table 3). Differences in body weight could not be accounted for by differences in food consumption (not shown). Serum ALT activity increased dramatically in mice fed HFD from weeks 12 to 20, denoting the onset of hepatocellular injury and more severe NAFLD (Table 3). Serum ALT failed to increase in HFD-fed DE-treated mice (Table 3), indicating that in addition to limiting HFD-induced adiposity, DE treatment in established obesity suppresses the progression of existing NAFLD. Histological assessment of liver tissue from mice at the end of the 20-week evaluation period indicated lower extent of microvesicular steatosis, the form of lipid accumulation spe-

**Table 1. Analysis of TAT, D-dimer, and PF4 in plasma from WT and Fibγ390–396A fed a CD or HFD for 20 weeks**

<table>
<thead>
<tr>
<th>Plasma marker</th>
<th>CD WT</th>
<th>Fibγ390–396A WT</th>
<th>HFD WT</th>
<th>Fibγ390–396A HFD</th>
</tr>
</thead>
<tbody>
<tr>
<td>TAT (μg/l)</td>
<td>9.1 ± 1.1</td>
<td>9.7 ± 1.6</td>
<td>17.6 ± 3.5</td>
<td>18.8 ± 3.8&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>D-dimer (ng/ml)</td>
<td>6477 ± 79.1</td>
<td>469.8 ± 61.2</td>
<td>950.5 ± 52.5&lt;sup&gt;b&lt;/sup&gt;</td>
<td>873.2 ± 130.0&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>PF4 (ng/ml)</td>
<td>461.6 ± 19.2</td>
<td>350.0 ± 12.0&lt;sup&gt;0&lt;/sup&gt;</td>
<td>455.7 ± 8.3</td>
<td>469.0 ± 18.7</td>
</tr>
</tbody>
</table>

For TAT, n = 4 and 12 per genotype for CD and HFD, respectively. For D-dimer and PF4, n = 4 and n = 8 per genotype for CD and HFD, respectively. Data are presented as the mean ± SEM and analyzed by ANOVA with Student-Newman-Keuls post hoc test. *P < 0.05, **P < 0.01, ***P < 0.001 for CD vs. HFD of the same genotype; ^P < 0.05 for WT vs. Fibγ390–396A on the same diet.
ogen) is a potent proinflammatory disease modifier of inflammatory arthritis, neuroinflammatory disease, muscular dystrophy, and colitis (35–38). Here, we show evidence of extensive fibrinogen deposition in both WAT and liver from obese mice that was absent in nonobese mice. These fibrinogen deposits appeared to serve as foci for the accumulation of macrophages. Importantly, a virtually identical fibrinogen staining pattern was observed in adipose tissue from obese patients, providing direct evidence in support of a role for this provisional matrix protein in human obesity-related disease.

Fibrinogen deposits in tissues may influence the obese phenotype through several non–mutually exclusive mechanisms. However, our data suggest that a key mechanism of protection from HFD-induced obesity observed in Fibγ390–396A mice is down-specifically associated with the most detrimental manifestations of NAFLD (data not shown) (34). In addition, DE treatment of HFD-fed mice provided a significant protection from HFD-induced increase in blood glucose levels (Table 3). Collectively, these studies are the first, to our knowledge, to demonstrate that intervention with a direct thrombin inhibitor attenuates the progression of HFD-induced obesity and its associated pathologies.

Discussion

A key objective of our studies presented here was to determine whether fibrinogen promotes exacerbation of HFD-induced obesity, adipose tissue inflammation, and the downstream development of metabolic sequelae. Supporting a functional role for fibrin deposits are previous findings indicating extravascular fibrinogen is a potent proinflammatory disease modifier of inflammatory arthritis, neuroinflammatory disease, muscular dystrophy, and colitis (35–38). Here, we show evidence of extensive fibrinogen deposition in both WAT and liver from obese mice that was absent in nonobese mice. These fibrinogen deposits appeared to serve as foci for the accumulation of macrophages. Importantly, a virtually identical fibrinogen staining pattern was observed in adipose tissue from obese patients, providing direct evidence in support of a role for this provisional matrix protein in human obesity-related disease.

Fibrinogen deposits in tissues may influence the obese phenotype through several non–mutually exclusive mechanisms. However, our data suggest that a key mechanism of protection from HFD-induced obesity observed in Fibγ390–396A mice is down-
regulation of adipose inflammation and ATM function. This hypothesis is supported by multiple previous studies. In 2 separate reports, the elimination of macrophages in mice resulted in significant protection from HFD-induced weight gain and adiposity analogous to the protection from obesity we observed in Fib390–396A mice (29, 30). The obesity phenotype is specifically associated with accumulation and activation of M1-polarized proinflammatory macrophages, whereas M2-polarized antiinflammatory macrophages are associated with a lean phenotype and protection from obesity (31, 39). It is possible that adipose fibrin(ogen) functions through the γ390–396 motif to drive ATMs to the obese M1 phenotype. Our gene expression analyses indicating reduced Tnf-α and Ccl2 mRNA expression in WAT from HFD-challenged Fib390–396A mice are consistent with this concept. Fibrin(ogen) γ390–396A may alter obesity by failing to stimulate M1 polarization or by actively promoting a protective M2 polarization in adipose. Although additional investigation is required to define the precise impact of fibrin(ogen) on macrophage activation in obesity, it is notable that we did not observe higher levels of M2 markers (e.g., Arg1) in WAT from HFD-challenged Fib390–396A mice (data not shown), suggesting that fibrin(ogen) γ390–396A expression results in a failure of M1 polarization, rather than an active shift toward an M2 phenotype.

A central question addressed by the current study was how fibrin(ogen) modifies the local expression of soluble mediators that influence the obesity phenotype. Notably, the genetic elimination or pharmacological depletion of either TNF-α or MCP-1 results in significant protection from HFD-induced insulin resistance and NAFLD (24, 26, 40). We observed significantly reduced local expression of Tnf-α mRNA levels in HFD-challenged Fib390–396A mice that tracked with protection from the development of glucose dysmetabolism and NAFLD. We postulate that the reduction in obesity sequelae is a function of diminished body weight and adiposity in HFD-fed Fib390–396A mice. However, the protection from HFD-induced NAFLD may be multifactorial, a product of reduced weight gain and reduced fibrin-driven inflammation in the liver. Notably, the single loss of either TNF-α or MCP-1 does not confer protection from weight gain and increased adiposity (24, 26, 40). This suggests that fibrin(ogen) alters the function of adipocytes or preadipocytes (a) through a requisite combination of soluble mediators, (b) through ATM-mediated mechanisms beyond the production of proinflammatory mediators, (c) by directly engaging adipocytes or preadipocytes, or (d) by some combination of these mechanisms. Diminished F4/80+ macrophages were observed in the eWAT of HFD-fed Fib390–396A mice, which was likely a product of overall reduced inflammation in these animals. In regard to adipocyte function, it is notable that when adipose tissue expands as a consequence of HFD feeding, preadipocytes are programmed to differentiate, permitting a hyperplastic expansion of functional adipocytes that preserves insulin sensitivity. Adipose infiltration by ATMs has been shown to promote an adipogenic deficit by suppressing preadipocyte differentiation (41, 42). It is possible that WAT fibrin(ogen) deposits promote both production of key proinflammatory soluble mediators that drive obesity sequelae and ATM-mediated suppression of preadipocyte differentiation.

Our studies directly implicate the γ390–396 motif in fibrin(ogen)-driven HFD-induced obesity. This motif supports binding to the leukocyte integrin receptor αβ2. A recent study documented significantly diminished adipose tissue inflammation as well as protection from HFD-induced insulin resistance and fatty liver disease in αγ-deficient mice, results that are complementary to our data (43). Intriguingly, HFD-fed αγ-deficient mice did not show protection from weight gain, suggesting either that various αγ ligands have opposing effects on HFD-induced WAT adiposity, or that the γ390–396 motif promotes WAT weight gain through mechanisms separate from αγ. In this regard, the β2-integrin family member αβ2 (CD11c/CD18) has been shown to bind fibrinogen through the γ390–396 domain and is expressed by monocytes/macrophages (44, 45). Inflammatory CD11c+ cells are significantly increased in obese adipose tissue and appear to contribute to the obese phenotype (46–48).

The coagulation transglutaminase factor XIII also binds the fibrinogen γ390–396 motif (23). F13a1 gene expression is significantly upregulated in WAT of both obese patients and mice fed a HFD (49, 50). Further, factor XIII has been suggested to act as a negative regulator of adipogenesis (50). Nevertheless, we show that loss of factor XIII activity does not phenocopy results observed in Fib390–396A mice, as F13a1+/− mice gain the same amount of weight as WT mice following HFD feeding. Collectively these findings suggest that the primary effect of the γ390–396A mutation in obes-

### Table 2. Summary of body weight, body composition, hepatocellular injury (ALT), and glucose for mice fed a CD or HFD for 12 weeks

<table>
<thead>
<tr>
<th>Diet</th>
<th>CD</th>
<th>HFD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body weight (g)</td>
<td>28.0 ± 0.7</td>
<td>41.3 ± 1.3†</td>
</tr>
<tr>
<td>Fat mass (%)</td>
<td>5.8 ± 0.8</td>
<td>22.2 ± 1.4†</td>
</tr>
<tr>
<td>Lean mass (%)</td>
<td>63.3 ± 0.6</td>
<td>61.0 ± 0.5†</td>
</tr>
<tr>
<td>ALT (U/l)</td>
<td>50.1 ± 6.1</td>
<td>79.2 ± 8.6†</td>
</tr>
<tr>
<td>Glucose (mg/dl)</td>
<td>165.3 ± 7.9</td>
<td>198.4 ± 7.6†</td>
</tr>
</tbody>
</table>

Data are presented as the mean ± SEM and analyzed by Student’s t test; †P < 0.05.

### Table 3. Summary of body weight, fat and lean mass, hepatocellular injury (ALT), and glucose changes induced by 8-week rescue treatment with DE

<table>
<thead>
<tr>
<th>Diet</th>
<th>CD</th>
<th>HFD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Impact of DE treatment (12–20 weeks)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Δ Body weight (g)</td>
<td>1.5 ± 0.3‡</td>
<td>0.8 ± 0.2</td>
</tr>
<tr>
<td>Δ Fat mass (%)</td>
<td>15.1 ± 8.7</td>
<td>8.9 ± 20.9</td>
</tr>
<tr>
<td>Δ Lean mass (%)</td>
<td>0.5 ± 1.0</td>
<td>1.3 ± 1.2</td>
</tr>
<tr>
<td>Δ ALT (U/l)</td>
<td>−38.5 ± 8.5‡</td>
<td>−9.6 ± 3.1</td>
</tr>
<tr>
<td>Δ Glucose (mg/dl)</td>
<td>17.3 ± 14.0</td>
<td>−8.4 ± 9.7</td>
</tr>
</tbody>
</table>

Data are presented as the mean ± SEM and analyzed by ANOVA with Student-Newman Keuls post hoc test. ‡P < 0.05 for change in parameter at 20 vs. 12 weeks; †P < 0.05 for mice fed a HFD vs. CD (neither with DE); and †P < 0.05 for mice on the same diet treated vs. not treated with DE.
tivity is not mediated simply by a decrease in factor XIII binding. A recent study by Myneni and colleagues indicated that HFD-fed F13a1−/− mice gain the same amount of weight as WT mice, aligned with our findings, but that F13a1−/− mice had diminished adipose tissue inflammation and were protected from insulin resistance (51). It was suggested that the mechanism of factor XIII exacerbation of adipose inflammation and obesity sequelae was linked to fibronecatin (51); however, a possible link to fibrinogen was not considered. We postulate that factor XIII may be influencing HFD-induced pathologies through a mechanism whereby cross-linked fibrin drives a greater proinflammatory response and has a greater impact on ATM function than non–cross-linked fibrin, a general hypothesis supported by previous work in our laboratory (52). However, defining the precise interplay of fibrinogen and factor XIII in obesity sequelae, including insulin resistance and NAFLD, remains for future investigation.

The identification of fibrinogen as a potent modifier of obesity implicates both upstream coagulation system components and downstream fibrinolytic factors as potential obesity modifiers. In this regard, elevated circulating levels of tissue factor (TF) and factor VII have been documented in obese patients with T2D and in mice fed a HFD (9, 10). High levels of bloodborne TF are considered a biomarker of severe microvascular disease in T2D patients (53, 54). Further, TF mRNA levels and activity are increased in the visceral adipose tissue of obese mice; specifically, TF expression is high in infiltrating ATMs (55, 56). Direct evidence of a causative relationship for TF in obesity was shown in mice lacking the cytoplasmic tail of TF, which conferred protection from HFD-induced weight gain and insulin resistance that was linked to TF/factor VIIa–mediated signaling by PAR2 in ATMs (57). Additionally, mice with low TF expression in the bone marrow compartment similarly were protected from HFD-induced weight gain (58). Here, we provide strong evidence that the TF/thrombin/fibrin/fibrinogen pathway also promotes obesity, glucose dysmetabolism, and fatty liver disease. Fibrinolytic/plasminogen activation system components have been long been associated with obesity and metabolic syndrome. In particular, plasminogen activator inhibitor-1 (PAI-1) is markedly elevated in obese patients and is considered a biomarker of obesity and metabolic syndrome (59–62). Visceral adipose tissue is the largest source of PAI-1 in obese patients and is derived from both adipocytes and infiltrating ATMs (62–65). The genetic elimination of PAI-1 in mice fed a HFD has been shown to result in diminished obesity and insulin resistance in several studies (66–69). In addition, mice deficient in tissue plasminogen activator (tPA) were shown to develop exacerbated obesity following HFD challenge (70). Collectively these findings are all consistent with the concept that persistent fibrin deposits drive diet-induced obesity.

Analyses of Thbd−/− mice indicated that these animals develop exacerbated HFD-induced obesity and associated sequelae. Although it is possible that the increased obesity observed in these animals was secondary to loss of Thbd antiinflammatory mechanisms, our data are consistent with our prevailing hypothesis that it is exacerbated thrombin procoagulant function driving HFD-induced obesity in these mice. Indeed, our finding that therapeutic DE administration effectively halts the progression of obesity-associated sequelae in mice suggests that targeting thrombin may be a beneficial therapeutic approach. Previous studies showed that intervention with another thrombin inhibitor, argatroban, significantly reduced systemic inflammation and plasma cholesterol levels in mice with established hypercholesterolemia and obesity (71). Could the novel oral anticoagulants (NOACs), currently relegated to antithrombotic therapy, be therapeutically beneficial in patients with established obesity? Obesity and its sequelae often coexist with atrial fibrillation, a primary indication for NOAC therapy (72). Notably, weight loss itself has been shown to reduce stroke risk associated with atrial fibrillation (73). Thus, NOAC therapy in patients with an existing indication may confer an additional metabolic benefit. Although the treatment strategy is anchored in strong and reproducible experimental results, the idea of treating patients with metabolic syndrome and obesity with NOACs may ultimately tip the risk/benefit balance to favor this possibility.

In this study, we define a novel mechanism of inflammation in experimental obesity mediated by the fibrinogen leukocyte integrin αvβ3–binding motif. Through gain- and loss-of-function studies targeting thrombin generation and downstream substrates, these studies are, to our knowledge, the first to ascribe thrombin-driven obesity to a function of fibrinogen and not PAR1 signaling. Moreover, to our knowledge, these studies are the first to experimentally demonstrate that procoagulant mutations are capable of exacerbating obesity-association sequelae, authenticating association studies in humans (16, 17, 74).

The deciphered mechanism is responsive to modulation with thrombin-targeted FDA-approved therapeutic agents. More specifically, fibrin-driven obesity appears amenable to targeted inhibition of the fibrinogen γ90–96 motif. In summary, the thrombin/fibrinogen axis is not only a critical trigger of HFD-mediated systemic inflammation, but a pharmacologically and genetically adjustable driver of obesity and related pathologies such as NAFLD and glucose dysmetabolism.

Methods

Mice. Thbd−/−, Fgg 390–396A (Fibγ90–96A), Fgg Δ5 (FibΔ5), F13α1−/−, and F2r−/− mice backcrossed 7 generations to C57BL/6 were all previously described (20, 21, 75–77). Age-matched littersmates of WT and homozygous mutant male mice between the ages of 8 and 12 weeks were used. For DE experiments, male C57BL/6J mice at 6 weeks of age were purchased from the Jackson Laboratory and allowed to acclimate in the animal facility for 2 weeks before being enrolled in studies. Mice were housed at an ambient temperature of 22°C with alternating 12-hour light/12-hour dark cycles, and provided water and rodent chow ad libitum before study initiation.

HFD-induced obesity. Mice were fed ad libitum a CD of standard mouse chow that provides about 13% of the kilocalories (kcal) derived from fat (Laboratory Autoclavable Rodent Diet 5010; LabDiet) or a HFD with 60% of the kcal derived from fat (catalog D12492; Research Diets Inc.). In some experiments, mice were fed a CD with 10% of the kcal derived from fat (catalog 56834; Test Diet) or a HFD with 45% of the kcal derived from fat (catalog 55629; Test Diet). In DE studies, mice...
were fed a 60% HFD (catalog 112252; Dyets Inc.) identical to catalog D12492 from Research Diets Inc. with or without 7.5 mg/g DE. Control mice were fed modified AIN-93M CD (Dyets Inc., 10% of kcal derived from fat) with or without 7.5 mg/g DE. Both the HFD and the CD with and without DE were formulated to contain 1% peanut flavoring to mask the bitter taste of the drug. Note that terminal circulating DE concentrations were determined for each group and found to be 388.2 and 248.0 ng/ml for the CD and HFD groups, respectively, in the pro-
congenrations were determined for each group and found to be 388.2 and 248.0 ng/ml for the CD and HFD groups, respectively, in the pro-
congenrations were determined for each group and found to be 388.2 and 248.0 ng/ml for the CD and HFD groups, respectively, in the pro-
congenrations were determined for each group and found to be 388.2 and 248.0 ng/ml for the CD and HFD groups, respectively, in the pro-
congenrations were determined for each group and found to be 388.2 and 248.0 ng/ml for the CD and HFD groups, respectively, in the pro-
congenrations were determined for each group and found to be 388.2 and 248.0 ng/ml for the CD and HFD groups, respectively, in the pro-

**Histopathology and clinical chemistry.** Mouse eWAT and a medi-
al or left lateral lobe of the liver were used for histological analysis. Biopsy samples of human visceral adipose tissue were obtained from the Cincinnati Children’s Hospital Pediatric Obesity Tissue Repository from obese patients with either normal liver histology or a histologically confirmed diagnosis of NASH. Tissue sections of visceral adipose tissue from nonobese individuals were obtained from Origene. Formalin-fixed tissue sections (5 μm) were stained with H&E or by immunohistochemistry with either a rabbit polyclonal anti-mouse fibrinogen antibody (previously described in ref. 36) or a monoclonal anti-human fibrinogen antibody (reference A0080; Dako). Fibrinogen staining was quantified using ImageJ (NIH). Epididymal adipose tissue sections, stained with F4/80 (catalog MCA497G; Bio-Rad Laboratories) were scanned and digitized using a Virtual Slide System VS110 (Olympus). The area of individual adipocytes was calculated using Olympus cellSens Dimension Desktop Software (version 1.15). Specifically, 50 individual adipocytes selected from at least 5 different areas of the digitized sections were analyzed per sample.

For genetically modified mice, blood was collected at the end of the observation period from the inferior vena cava in citrate. For studies where mice were treated with DE-containing chow, blood was collected by retro-orbital bleeding after 12 weeks on CD or HFD and analyzed for serum alanine aminotransferase (ALT) and glu-
cose levels. ELISA analysis was used to determine the plasma levels of TAT complexes (Siemens Enzygnost TAT kit), D-dimer (Biomatik Mouse D-dimer kit), and PF4 (RayBio Mouse PF-4 ELISA kit). Serum ALT activity was determined using a commercially available reagent (Thermo Fisher Scientific). Plasma cytokines, chemokines, and adi-
pokines were determined using Milliplex Magnetic Bead multiplex or single-plex kits (Millipore) and read using a Bio-Plex (Bio-Rad Labor-
datories). Concentrations were calculated from standard curves using recombinant proteins and expressed in picograms per milliliter or micrograms per milliliter.

For analysis of blood glucose, mice were fasted for 6 hours fol-
followed by blood glucose measurements taken using an ACCU-check Performa meter (Roche) from a tail vein blood sample. Glucose toler-
ance tests were performed after 16 weeks on diet. Mice were fasted for 6 hours, and dextrose was administered by i.p. injection at a dose of 1 g/kg mouse body weight with blood glucose readings taken at 15-minute intervals. Insulin tolerance tests were performed on mice after 18 weeks on diet. Human recombinant insulin (Novolin-R; Novo Nordisk) was administered by i.p. injection at a dose of 0.75 U/kg body weight. Blood glucose readings were taken at 15-minute intervals. For both glucose and insulin tolerance tests, AUC was determined for blood glucose profiles from individual mice.

**Hepatic triglyceride determination.** Hepatic triglyceride content was determined as described previously (78). Briefly, 100 mg of frozen liver tissue was homogenized, mixed with chloroform/methanol (2:1), and incubated overnight at room temperature. Subsequently, H2O was added with collection of the lower lipid phase by centrifugation and vacuum concentration. The lipid pellets were dissolved in a mixture of isopropanol and Triton X-100 and analyzed spectrophotometrical-
ly for triglycerides (600 nm) using commercially available reagents (Ponte Scientific).

**RNA isolation, cDNA synthesis, and real-time PCR.** Total RNA was isolated from 100 mg of tissue using Trizol (Ambion) according to the manufacturer’s protocol. RNA (1 μg) was used for cDNA syn-
thesis with a High Capacity cDNA Reverse Transcription kit (Applied Biosystems). Levels of TNF-α (Tnf), MCP-1 (Ccl2), F4/80 (Adgre1), PPARY (Pparg), CIDEA (Cidea), CD36 (Cd36), UCP1 (Ucp1), UCP2 (Ucp2), and β2-microglobulin (B2m) were determined using TaqMan gene expression assays (Applied Biosystems) on an ABI StepOnePlus sequence detection system (Applied Biosystems). The expression of each gene was normalized relative to B2m expression levels, and rela-
tive expression level determined using the Pfaffl method (79).

**Detection of fibrinogen by capillary Western blotting.** To assess WAT levels of cross-linked high-molecular weight fibrinogen (fibrinogen-100), 100 mg of eWAT was homogenized in 8 M urea, 40 mM DTT, 12.5 mM EDTA based on protocols outlined previously (23, 80), rotated end over end in a 60°C incubator for 2 hours, and incubated stationary at 60°C overnight (~15 hours). Samples were collected by centrifugation and resolved on Wes 66- to 440-kDa 25-microcapillary gels (Protein Simple). Fibrinogen was detected with polyclonal rabbit anti-human fibrinogen antibody (reference A0080; Dako) per the manufacturer’s protocol (Protein Simple). To identify precise species, in vitro fibrin polymerization was performed using citrated WT and F13a1−/− mouse plasma, stimulated with human α-throm-in (2 U/ml final) (Enzyme Research Laboratories) in a CaCl2 (10 mM final) buffer for 30 minutes at 37°C. Samples were processed in urea/DTT/EDTA buffer, and fibrinogen species were detected using capillary Western blot.

**Intestinal fat absorption.** Mice were fed with a CD or 60% HFD for 16 weeks, after which a diet containing 5% sucrose polybehenate, a nonabsorbable food additive, was fed to the mice ad libitum for 3 days. Fecal pellets were collected on days 3 and 4. Fat absorption was calcu-
lated from the ratios of behenic acid to other fatty acids in the diet and in the feces by gas chromatography of fatty acid methyl esters.

**Statistics.** In studies in which the weights of mice over time were determined, the data were analyzed by repeated-measures ANOVA. Comparison of 2 groups was performed using a 2-tailed Student’s t test. Comparison of 3 or more groups was performed using 1-way or 2-way ANOVA and Student-Newman-Keuls post hoc test. P values for all comparisons are indicated in the figure legends, but for all analyses the criterion for statistical significance was P less than 0.05. **Study approval.** Mice were maintained in Association for Assessment and Accreditation of Laboratory Animal Care International–accredited facilities and approved by the IACUC at Cincinnati Children’s Hospital.
Author contributions

AKK, SRA, SD, JPL, and MJF designed the study, performed experiments and data analysis, and participated in the writing of the manuscript. ST, JSP, ESM, HW, APO, and NM were involved with conception of the project, data analysis, and writing of the manuscript. AG and JvR provided DE and assisted with conception of the project and editing of the manuscript. All authors contributed to final editing of the manuscript.

Acknowledgments

We thank Carolina Cruz, Alice Jone, Cheryl Rewerts, Traci Stankiewicz, and Maureen Shaw for their excellent technical assistance. This work was supported by a research contract from Boehringer Ingelheim (to JPL), grants DK099222 (to SD), ESOI7537 (to JPL), and HL112603 (to MJF) from the NIH, and a Pilot and Feasibility grant (to MJF) through NIH grant P30 DK078392 of the Digestive Diseases Research Core Center at Cincinnati Children’s Hospital Medical Center.

Address correspondence to: Matthew J. Flick, Division of Experimental Hematology and Cancer Biology, Cincinnati Children’s Hospital, 333 Burnet Avenue, Cincinnati, Ohio 45229-3039, USA. Phone: 513.636.6628; Email: matthew.flick@cchmc.org.


